Frontlight ResearchEarly access
Pancreatic cancer trials in Finland
1 of 13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleA Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Where
- Helsinki
- Age
- 18 years to 99 years
- People
- 24,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05663515